Glenmark UK > Oncology > Preliminary Biomarker And Pharmacodynamic Data From A Phase 1 Study Of Single-Agent Bispecific Antibody T Cell Engager GBR 1302 In Subjects With Her2‐Positive Cancers
Product Catalog
This is a widget ready area. Add some and they will appear here.
Preliminary Biomarker And Pharmacodynamic Data From A Phase 1 Study Of Single-Agent Bispecific Antibody T Cell Engager GBR 1302 In Subjects With Her2‐Positive Cancers
